Successful treatment discontinuation in CML patients with full-dose and low-dose TKI: Results from real-world practice

Successful treatment discontinuation in CML patients with full-dose and low-dose TKI: Results from real-world practice

Background: In clinical studies, some patients who achieve deep molecular response (DMR) can successfully discontinue tyrosine kinase inhibitor (TKI). TKI dose reduction is also an important aspect of alleviating adverse effects and improving quality of life. This study aimed to explore the outcome...

Full description

Bibliographic Details
Main Authors:	Yilin Chen, Huifang Zhao, Jingming Guo, Jing Zou, Wenjuan He, Danlei Han, Fanjun Cheng, Yanli Zhang, Weiming Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-01-01
Series:	Frontiers in Pharmacology
Subjects:	chronic myeloid leukemia tyrosine kinase inhibitor dose reduction treatment free remission real-world practice
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1101743/full

Similar Items

Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study
by: A. Iurlo, et al.
Published: (2023-03-01)

Quality‐of‐life, mental health, and perspective on TKI dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemia
by: Yilin Chen, et al.
Published: (2023-08-01)

Treatment-Free Remission in Chronic Myeloid Leukemia and New Approaches by Targeting Leukemia Stem Cells
by: Yilin Chen, et al.
Published: (2021-10-01)

Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings
by: Fang Cheng, et al.
Published: (2023-04-01)

Evaluation of tyrosine kinase inhibitor discontinuation initiative in patients with chronic myeloid leukemia at princess noorah oncology center
by: Afnan Mohammed Noor, et al.
Published: (2022-01-01)

The efficacy and safety of eltrombopag in treating TKI-induced thrombocytopenia in patients with chronic myeloid leukemia
by: Li Liu, et al.
Published: (2023-12-01)

Chronic Myeloid Leukemia, from Pathophysiology to Treatment-Free Remission: A Narrative Literature Review
by: Rinaldi I, et al.
Published: (2023-04-01)

Monitoring the response to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML)
by: Ibrahim C. Haznedaroglu
Published: (2014-08-01)

Incidences of Deep Molecular Responses and Treatment-Free Remission in de Novo CP-CML Patients
by: Gabriel Etienne, et al.
Published: (2020-09-01)

Budget Impact analysis of the first-line treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) adult patients
by: Francesco Mennini, et al.
Published: (2017-07-01)

Delayed Diagnosis and Multi-TKI Intolerance: A Case Report of CML Concurrent With COVID-19
by: Chengxin Luan, et al.
Published: (2022-06-01)

Combination of PKCδ Inhibition with Conventional TKI Treatment to Target CML Models
by: Fabien Muselli, et al.
Published: (2021-04-01)

Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation
by: Simona Bernardi, et al.
Published: (2019-05-01)

Treatment free remission in chronic myeloid leukemia: Lights and shadows
by: Matteo Molica, et al.
Published: (2020-09-01)

Determination of a radotinib dosage regimen based on dose–response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia
by: Hayeon Noh, et al.
Published: (2018-05-01)

A Real-World Evidence-Based Study of Long-Term Tyrosine Kinase Inhibitors Dose Reduction or Discontinuation in Patients with Chronic Myeloid Leukaemia
by: Alicia Martín Roldán, et al.
Published: (2023-04-01)

Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal
by: Carolina Pavlovsky, et al.
Published: (2023-04-01)

Spontaneous Remission in a Patient with Chronic Myeloid Leukemia: A Case Report
by: Awni Alshurafa, et al.
Published: (2023-10-01)

Allogeneic Transplantation In Chronic Myeloid Leukemia And The Effect Of Tyrosine Kinase Inhibitors On Survival, A Quasi-Experimental Study
by: Mehmet Özen, et al.
Published: (2017-02-01)

In-depth characterization of NK cell markers from CML patients who discontinued tyrosine kinase inhibitor therapy
by: María Belén Sanchez, et al.
Published: (2023-09-01)

Use of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia (CML)
by: C. B. Almeida, et al.
Published: (2016-11-01)

Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia With Losing Major Molecular Response as a Definition for Molecular Relapse: A Systematic Review and Meta-Analysis
by: Kang-kang Chen, et al.
Published: (2019-05-01)

The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients
by: Anastasia Putri, et al.
Published: (2019-10-01)

Chronic myeloid leukemia patients and treatment-free remission attitudes: a multicenter survey
by: Lou J, et al.
Published: (2018-06-01)

Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
by: Francesca Carofiglio, et al.
Published: (2020-06-01)

Dynamical Systems Properties of a Mathematical Model for the Treatment of CML
by: Urszula Ledzewicz, et al.
Published: (2016-10-01)

Molecular Testing in CML between Old and New Methods: Are We at a Turning Point?
by: Simona Soverini, et al.
Published: (2020-11-01)

Treatment-free remission in patients with chronic myeloid leukemia: literature review
by: A. N. Petrova, et al.
Published: (2019-10-01)

Accelerated Phase Chronic Myeloid Leukemia and Treatment Free Remission Maintained After Five Years of Nilotinib: A Case Report
by: Isabella Capodanno, et al.
Published: (2021-06-01)

Serum Calcium And Phosphateleveelsin Patients With Chronic Myeloid Leukemia Taking Different Dose of Tyrosine Kinase Inhibitors
by: Bassam Francis Matti, et al.
Published: (2018-03-01)

Efficacy of nilotinib therapy in patient with CML diagnosed in pre-TKI era and resistant to imatinib
by: Ivana Pierri, et al.
Published: (2015-10-01)

Full dose, half dose, or discontinuation of etanercept biosimilar in early axial spondyloarthritis patients: a real-world study in China
by: Kun-Peng Li, et al.
Published: (2018-06-01)

Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network
by: Giorgina Specchia, et al.
Published: (2021-08-01)

Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge
by: Alessandra Iurlo, et al.
Published: (2021-02-01)

Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors
by: Jee Hyun Kong, et al.
Published: (2020-05-01)

Clinical and Psychological Factors to Consider in Achieving Treatment-Free Remission in Patients With Chronic Myeloid Leukemia
by: Massimo Breccia, et al.
Published: (2021-03-01)

Pre‐and post‐HSCT use of TKI therapy for fusion‐driven B‐ALL: A case series of five pediatric, adolescent and young adult patients
by: Savannah S. Shumock, et al.
Published: (2023-12-01)

Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy
by: Zhenshu Xu, et al.
Published: (2009-03-01)

A review of the therapeutic role of the new third-generation TKI olverembatinib in chronic myeloid leukemia
by: Honglan Qian, et al.
Published: (2022-12-01)

Exploration of treatment‐free remission in CML, based on molecular monitoring
by: Zhao Zhang, et al.
Published: (2024-01-01)